EMEDOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Electromedical Technologies, Inc
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$0.00+0.00 (+9900.00%)
Close on Oct 19, 2026
- Market cap
- $68.10K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2023
Gross margin
77.5%
Operating margin
-153.1%
Net margin
-195.8%
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.3% | +22.3% | – | – | |
| Gross profit | +17.7% | +24.4% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 103.7% | |
| Return on assets | – | – | -251.3% | |
| Current ratio | – | – | 0.13 | |
| Interest coverage | – | – | -2.3× | |
| Inventory turnover | – | – | 4.6× | |
| Diluted shares | – | – | 377M |
Cash use needs five years of cash flow figures
Electromedical Technologies does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-195.8%
×Asset turnover1.28×
×Equity multiplier-0.41×
=Return on equity, FY2023103.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -195.8% | 1.28× | -0.41× | 103.7% |
| FY2022 | -301.6% | 0.83× | -0.94× | 235.7% |
| FY2021 | -934.6% | 0.64× | -1.38× | 830.9% |
| FY2020 | -524.7% | 0.64× | -0.66× | 221.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
4of 8 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.64M
- Cash generatingOperating cash flow above zero-$1.42M
- Return on assets improvedROA up on the prior year-247.4% → -195.2%
- Earnings backed by cashOperating cash flow above net income-$1.42M vs -$2.64M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.22 → 0.13
- No dilutionShare count did not rise134M → 377M
- Gross margin improvedGross margin up on the prior year77.28% → 77.51%
- More efficientAsset turnover rose0.82 → 1.00